

Biocon posts Rs 2,476 Cr revenue in Q4FY22

29 April 2022 | News

The FY22 revenue has been registered at Rs 8,397 crore



In Q4FY22 Biocon has registered revenue of Rs 2,476 crore, up 21 per cent; core EBITDA has been posted at Rs 815 crore, up 37 per cent; PBT(before Exceptional Items) is at Rs 384 crore, up 9 per cent. The biosimilars is up 48 per cent at Rs 982 crore; generics up 26 per cent at Rs 717 crore. Research services is up 15 per cent at Rs 758 crore.

FY22 revenue has been posted at Rs 8,397 crore, up 14 per cent; the core EBITDA is up 18 per cent at Rs 2,669 crore, PBT (before Exceptional Item) has been registered at Rs 1094 crore, up 4 per cent.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said, "FY22 was a transformational year for Biocon. Key strategic moves in our biosimilars business position us for long-term growth and value creation for our stakeholders. We believe that the two strategic transactions, with Viatris and Serum Institute Life Sciences, will position Biocon Biologics as a world leading, unique, fully integrated biologics company with a strong differentiated portfolio of biosimilars and vaccines."